Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15897595 | 0.89 | FAAH (0.56) | GAAL3MBTL1CA1CA2KMT2A | |
| SCHEMBL17452431 | 0.84 | MAPT (0.58) | GAAL3MBTL1CA1CA2KMT2A | |
| SCHEMBL17453758 | 0.81 | MAPT (0.68) | GAAL3MBTL1CA1CA2KMT2A | |
| SCHEMBL27177969 | 0.75 | MAPT (0.65) | GAAL3MBTL1KMT2ASMN1; SMN2RAB9A | |
| SCHEMBL27177964 | 0.75 | MAPT (0.65) | GAAL3MBTL1KMT2ASMN1; SMN2RAB9A | |
| SCHEMBL9523014 | 0.74 | S1PR4 (0.69) | GAAL3MBTL1KMT2ASMN1; SMN2POLB | |
| SCHEMBL15897537 | 0.73 | — | — | |
| SCHEMBL17453764 | 0.73 | MEN1 (0.58) | GAAL3MBTL1CA1CA2KMT2A | |
| SCHEMBL30051979 | 0.73 | MAPT (0.67) | GAAL3MBTL1KMT2ASMN1; SMN2POLB | |
| SCHEMBL20080851 | 0.73 | LMNA (0.72) | L3MBTL1KMT2ASMN1; SMN2POLBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160016930-A1 | PROTECTIVE MOLECULES AGAINST ANTHRAX TOXIN | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016930-A1 | PROTECTIVE MOLECULES AGAINST ANTHRAX TOXIN | ANTXR2, TSG101, ANXA1 | GAA 1322/4885L3MBTL1 794/4885CA1 1178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.